Journal of the Academy of Consultation-Liaison Psychiatry最新文献

{"title":"CL Case Conference: Treatment Over Objection in the General Hospital.","authors":"Natasha R Pillai, Adira Hulkower, Shane Gallagher, Cyril Abraham, Rubiahna Vaughn","doi":"10.1016/j.jaclp.2025.05.006","DOIUrl":"https://doi.org/10.1016/j.jaclp.2025.05.006","url":null,"abstract":"<p><p>We present the case of a 65-year-old female with schizophrenia admitted to the general hospital for a urinary tract infection complicated by psychotropic non-adherence and severe agitation. Treatment over objection (TOO) for UTI and underlying severe mental illness was granted by the court. However, treatment was delayed by staff discomfort and unfamiliarity with TOO and further complicated by the patient's ongoing psychosis and agitation. The multidisciplinary team provides commentary and guidance on the management of this commonly encountered scenario. Key teaching points include the ethical dilemmas of TOO, goals of TOO and difficulties implementing TOO in the general hospital from both physician and nursing perspectives. We discuss the logistical barriers hindering implementation of TOO in the general hospital setting, the pivotal role of the consultation-liaison psychiatrist and provide a general guide for implementing TOO in the general hospital.</p>","PeriodicalId":52388,"journal":{"name":"Journal of the Academy of Consultation-Liaison Psychiatry","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144182258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clozapine in solid organ transplant: a literature review and case series.","authors":"Judith Allison Restrepo, Blake L Rosenbaum, Daniel Harris, Thais Gift, Oliver Freudenreich","doi":"10.1016/j.jaclp.2025.05.007","DOIUrl":"https://doi.org/10.1016/j.jaclp.2025.05.007","url":null,"abstract":"<p><p>Current experience with the management of clozapine in patients needing solid organ transplant (SOT) is sparse. Clozapine is an essential antipsychotic for many patients with treatment-resistant schizophrenia that cannot be replaced by other antipsychotics without the risk of psychotic relapse. However, clozapine is associated with many side effects, including neutropenia, that may interact with immunosuppressive therapies during organ transplantation. We conducted a literature review of clozapine use during SOT and a retrospective case review using natural language processing of the Partners Research Patient Data Registry to identify individuals over age eighteen who had taken clozapine at any time and been evaluated for or undergone SOT- we identified fifteen patients who met this criterion. Three patients underwent renal transplantation while remaining on clozapine and one patient started clozapine after renal transplant, all without complication. We additionally have included an illustrative case report to summarize our direct experience of continuing clozapine through lung transplant, highlighting the first known case in this population. Finally, we provide clinical guidance for management of clozapine and associated side effects during SOT. Proactive consultation with psychiatry may avoid abrupt cessation of clozapine, which can result in severe clozapine withdrawal, and increase the number of patients on clozapine considered for SOT.</p>","PeriodicalId":52388,"journal":{"name":"Journal of the Academy of Consultation-Liaison Psychiatry","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144183677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hallucinations and related perceptual phenomena in systemic lupus erythematosus and inflammatory arthritis: a cross-sectional mixed methods study.","authors":"Arjoon Arunasalam, Thomas A Pollak, Avni Varshney, James A Bourgeois, David D'Cruz, Guy Leschziner, Mervi Pitkanen, Alessandra Bortoluzzi, Lucy Calderwood, Kaira Naidu, Elaine Dunbar, Laura Andreoli, Martha Piper, Sydnae Taylor, Melanie Sloan","doi":"10.1016/j.jaclp.2025.05.005","DOIUrl":"https://doi.org/10.1016/j.jaclp.2025.05.005","url":null,"abstract":"<p><strong>Background: </strong>The INSPIRE research project explored neuropsychiatric symptoms associated with Systemic Autoimmune Rheumatic Diseases (SARDs), identifying hallucinatory experiences as a lesser known but impactful symptoms. Following consultations with clinicians and patients, areas of focus included the prevalence, sensory modalities, insight, timings, and emotional valence of hallucinations in SARDs. Our previous research shows that hallucinations and related perceptual phenomena often go unreported and unrecognised in clinical settings with SARD patients.</p><p><strong>Objective: </strong>This study analyses and compares hallucination experiences in patients with systemic lupus erythematosus (SLE) and inflammatory arthritis (IA). We evaluated prevalence, modalities, insight, emotional valence, and timings of hallucinations.</p><p><strong>Methods: </strong>Quantitative data from cross-sectional surveys (n=1022) and qualitative data from interviews were integrated using mixed methods. Quantitative data are presented descriptively and comparatively (using Pearson's χ2 tests), and qualitative data were analysed thematically.</p><p><strong>Results: </strong>SLE patients reported a greater lifetime prevalence of hallucinations compared to IA patients, with significant differences in visual (12% vs 6%), olfactory (11% vs 6%), tactile (11% vs 5%), and presence (10% vs 3%) modalities (all p<0.005). Auditory hallucinations were not significantly more frequent in SLE (8%) compared to IA (5%) (p =0.071). Consistent lack of insight into hallucinations was rare (11% of SLE, and 4% of IA patients). SLE patients were significantly more likely to experience hallucinations in contexts unrelated to periods of sleep transition than IA patients (p =0.020). Recognizing hallucinations as SARD symptoms helped patients develop positive coping mechanisms and reduced distress. However, fear of clinician judgment, stigma, and misdiagnoses discouraged reporting.</p><p><strong>Conclusion: </strong>The higher prevalence in SLE likely reflects its greater direct impact of SLE (compared to IA) on the brain. Hallucinatory experiences in SARDs aligned more closely with neurological diseases than primary psychotic disorders. Understanding the varying modalities and contexts of hallucinations as potential direct effects of SLE could improve attribution, treatment, and coping strategies, while reducing stigma and fostering open communication between patients and clinicians.</p>","PeriodicalId":52388,"journal":{"name":"Journal of the Academy of Consultation-Liaison Psychiatry","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mentorship in the Academy of Consultation-Liaison Psychiatry.","authors":"Scott R Beach, David P Kasick, Priya Gopalan, Carrie L Ernst","doi":"10.1016/j.jaclp.2025.05.004","DOIUrl":"10.1016/j.jaclp.2025.05.004","url":null,"abstract":"","PeriodicalId":52388,"journal":{"name":"Journal of the Academy of Consultation-Liaison Psychiatry","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual orexin receptor antagonists for delirium: A scoping review and feasibility trial of daridorexant.","authors":"Mark A Oldham, Heather L Lander, Joy J Choi, Marjorie S Gloff, Peter A Knight, Jacob W Nadler","doi":"10.1016/j.jaclp.2025.05.003","DOIUrl":"https://doi.org/10.1016/j.jaclp.2025.05.003","url":null,"abstract":"<p><strong>Background: </strong>No medication is currently approved either for the prevention or treatment of delirium despite its tremendous clinical impact. Sleep-wake disturbances offer a promising target for delirium therapeutics, with a growing body of literature suggesting a potential role of dual orexin receptor antagonists (DORAs). This report provides a scoping review of the literature on DORAs for delirium and the results of a feasibility trial of daridorexant to prevent delirium after heart surgery.</p><p><strong>Methods: </strong>We conducted a scoping review according to PRISMA for Scoping Reviews guidelines for peer-reviewed reports of DORAs for delirium. Next, we report sample characteristics and results for the feasibility aims from our single-site, double-blind, randomized placebo-controlled feasibility trial of daridorexant 50 mg given the first three nights after heart surgery to prevent delirium.</p><p><strong>Results: </strong>Our scoping review includes 30 reports, 4 case reports/series, 1 clinical effectiveness project, 22 retrospective cohort studies and 3 clinical trials. This literature is authored almost exclusively by teams from Japan. Most publications are on suvorexant. Although published data suggest a potential role for DORAs to prevent delirium, they remain inconclusive. We demonstrate the feasibility of our study (n = 11). In this preliminary trial, daridorexant arm subjects had a numerically lower mean delirium symptom burden on postoperative days 1-3.</p><p><strong>Discussion: </strong>The evidence in support of DORAs for delirium calls for adequately powered efficacy trials. We also emphasize the importance of considering the pharmacokinetics of DORAs for delirium to maximize potential benefit and minimize the risk of next-morning sedation.</p>","PeriodicalId":52388,"journal":{"name":"Journal of the Academy of Consultation-Liaison Psychiatry","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144081978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Catatonia: American Psychiatric Association Resource Document.","authors":"Jo Ellen Wilson, Mark A Oldham, Andrew Francis, Dina Perkey, Eric Kramer, Shixie Jiang, Jennifer Yoon, Scott Beach, Gregory Fricchione, Matthew Gunther, Jihoon Ha, James Luccarelli, Jordan Rosen, Dallas Hamlin, Joseph D Dragonetti, Avi Gerstenblith, Anne Louise Stewart, Jon Sole, James A Bourgeois","doi":"10.1016/j.jaclp.2025.05.001","DOIUrl":"https://doi.org/10.1016/j.jaclp.2025.05.001","url":null,"abstract":"<p><p>The American Psychiatric Association Resource Document for Catatonia was prepared by the Catatonia Work Group of the Council on Consultation-Liaison Psychiatry, with the goal of supporting psychiatrists, trainees and other mental healthcare workers and to provide a useful framework for understanding catatonia. This document is not intended to be comprehensive or completely systematic in nature, nor is it a practice guideline. In 2023, the American Psychiatric Association Council on Consultation-Liaison (C-L) Psychiatry convened a work group to develop a resource document on Catatonia. A draft of this document was reviewed by the Council in December 2024, and a revised version was approved by this Council in January 2025. The accepted version was subsequently reviewed by the American Psychiatric Association Council on Women's Mental Health, Council on Geriatric Psychiatry, Council on Research, Council on Quality Care, Committee on Practice Guidelines, and Committee on Ethics in December 2024. The final version was approved by the Joint Reference Committee on March 12th, 2025, and posted to the APA website. In this Resource Document we review the history of the catatonia, its epidemiology including prevalence and risk factors. We review the common evaluation methods including rating scales, diagnostic criteria and clinical evaluation of medical causes of catatonia and its complications, with a focus on the physical examination, laboratory studies, neuroimaging and electroencephalography. We review the differential diagnosis of catatonia across the medical and psychiatric context of care including: abulia / akinetic mutism, delirium, major neurocognitive disorders, locked in syndrome, late stage Parkinsons disease, Stiff Person Syndrome, Akathisia, mania, malignant catatonia / Neuroleptic Malignant Syndrome, autoimmune encephalitis, and Serotonin Syndrome. In this Resource Document we additionally review the pathophysiology of catatonia and highlight common interventions and treatment recommendations, with a focus on benzodiazepines and electroconvulsive therapy (ECT). We additionally highlight considerations in specific populations including pediatrics, the medically complex, pregnancy and postpartum period and dementia. We conclude the document with a review of ethical and legal considerations and provide some suggestions for educational resources.</p>","PeriodicalId":52388,"journal":{"name":"Journal of the Academy of Consultation-Liaison Psychiatry","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144081952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacologic Management of Skin-Picking Disorder: An Updated Review.","authors":"Nina Modanlo, Xiaofeng Yan, James A Bourgeois","doi":"10.1016/j.jaclp.2025.05.002","DOIUrl":"https://doi.org/10.1016/j.jaclp.2025.05.002","url":null,"abstract":"<p><strong>Introduction: </strong>Skin-picking disorder (SPD), defined as a psychocutaneous condition that involves excessive picking at the skin causing marked impairment in quality of life, is commonly seen in both dermatology and psychiatry. As such, therapeutic intervention - both non-pharmacologic and pharmacologic - is essential. Given the rising prevalence of SPD and the tremendous impact it can have on quality of life, an updated review, specifically on pharmacologic options, is very much needed.</p><p><strong>Methods: </strong>A search through PubMed was conducted using the key words \"treatment\" and \"skin picking\" or \"excoriation\" in November 2024. Articles were limited to those that solely address pharmacologic treatments in skin-picking for individuals > 18-years-old, were published in the last 20 years, in the English language, and can be classified as either a clinical trial, case report/series, or cohort study.</p><p><strong>Findings: </strong>Of the 192 articles extracted from PubMed, 13 studies (289 patients) met the inclusion criteria. These articles consist of 7 case reports/series and 6 randomized controlled trials. The following medications were evaluated for treatment of SPD: selective serotonin reuptake inhibitors (SSRIs), glutamatergic drugs (N-acetyl cysteine, memantine), antiepileptics (lamotrigine, topiramate), lithium, antipsychotics (olanzapine, aripiprazole), opioid antagonists (naltrexone), and mirtazapine.</p><p><strong>Conclusion: </strong>Of the medications evaluated for use in SPD, SSRIs show the most promising results in terms of mitigating the severity and frequency of skin-picking symptoms. Although habit-reversal psychotherapy has traditionally been first-line treatment, SSRIs are now increasingly being used in combination with psychotherapy when a patient presents with SPD. N-acetyl cysteine has also been well-established in the treatment of SPD. Other classes of medications that have been studied in SPD include the use of antipsychotics (often combined with antidepressants) and naltrexone. Additional studies are indicated to further expand on the current research and definitively establish the role of the less common medications, such as antiepileptics, in SPD.</p>","PeriodicalId":52388,"journal":{"name":"Journal of the Academy of Consultation-Liaison Psychiatry","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144008073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Comparative Study of Anticipatory Grief in Caregivers of Patients With Alzheimer's Disease and Hematological Malignancy.","authors":"Umut Türk, Makbule Çiğdem Aydemir, Erguvan Tuğba Özel-Kizil, Sinem Civriz Bozdağ","doi":"10.1016/j.jaclp.2025.04.003","DOIUrl":"10.1016/j.jaclp.2025.04.003","url":null,"abstract":"<p><strong>Background: </strong>Anticipatory grief (AG) is a common experience that affects caregivers of patients with chronic illnesses, particularly Alzheimer's disease. Cognitive disorders leading to social death produce a greater impact on the relationship, and thus on AG, than physical disorders.</p><p><strong>Objective: </strong>The purpose of this study is to examine the prevalence and severity of AG in caregivers of patients with major neurocognitive disorder due to Alzheimer's disease (MNCD-AD) compared to hematological malignancies and to identify the characteristics associated with AG.</p><p><strong>Methods: </strong>A total of 132 dyads (patients and their caregivers) completed measures of AG, caregiver burden, anxiety, and depressive symptoms, as well as mental status.</p><p><strong>Results: </strong>The point prevalence of significant AG was similar in the MNCD-AD (57.6%) and hematological malignancy (51.5%) groups. There was no statistically significant difference between the groups in terms of the severity of AG (48.77 ± 17.98 vs 44.18 ± 15.57, respectively). However, the personal sacrifice burden was significantly higher in the MNCD-AD group (P = 0.043). The severity of AG of caregivers is correlated with caregiver burden (r = 0.735), cognitive decline (r = 0.575), and neuropsychiatric symptoms (R = 0.627) of the MNCD-AD patient.</p><p><strong>Conclusions: </strong>The results of the study highlighted that the disease type can influence the AG of caregivers in a qualitative rather than a quantitative manner. Future studies are recommended to consider effects of psychological or interpersonal factors on AG. In addition, psychiatric comorbidities among family caregivers of MNCD-AD patients should be examined.</p>","PeriodicalId":52388,"journal":{"name":"Journal of the Academy of Consultation-Liaison Psychiatry","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144060424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proactive Addiction Consultation for Hospitalized Patients With Opioid Use Disorder: A Pilot Study.","authors":"David E Karol, Joshua D Cockroft, Christian J Pemberton, Caitlin Delong, Jeffrey Welge, Elizabeth Tiffany, Christine Wilder","doi":"10.1016/j.jaclp.2025.04.002","DOIUrl":"10.1016/j.jaclp.2025.04.002","url":null,"abstract":"<p><strong>Background: </strong>Opioid use disorder (OUD) negatively impacts individuals, communities, and health care systems with significant morbidity and mortality. There is a need for early intervention with hospitalized patients with OUD to improve health outcomes. Proactive consultation-liaison psychiatry, with and without electronic health record tools, is an effective way to reach more patients in need and to improve health services outcomes. The impact of proactive addiction consultation is unknown.</p><p><strong>Objective: </strong>To describe a pilot study examining the effects of proactive addiction consultation on service delivery and clinical outcomes for hospitalized patients with opioid use disorder.</p><p><strong>Methods: </strong>This quasi-randomized, controlled pilot study tested whether, in hospitalized patients with likely OUD, early identification and prompts to initiate consultation resulted in an increased proportion of consultations completed as compared to usual care. Secondary outcomes included initiation of medication for OUD, leaving against medical advice, emergency room utilization, and hospital readmission. An electronic health record-generated daily report was used to identify patients admitted to the hospital in the previous day with diagnoses synonymous with OUD (e.g., opioid abuse and opioid dependence) or often associated with a co-occurring OUD (e.g., bacterial endocarditis and accidental overdose). Individuals confirmed through further chart review as having a high likelihood of OUD were assigned to intervention versus treatment-as-usual in a standardized fashion. The intervention consisted of our research team suggesting an addiction consultation if the patient agreed. Primary teams for the treatment-as-usual participants were not contacted, and consultations were only completed if the primary team independently requested them.</p><p><strong>Results: </strong>Participants randomized to the intervention arm were significantly more likely to receive an addiction consultation (54.8% vs. 16.2%, P < 0.0001). There were no significant differences between the 2 groups in secondary outcomes. Secondary analyses showed that participants who received an addiction consultation (independent of group assignment) were significantly more likely to receive medication for OUD than those who did not (61.2% vs. 29.3%, P < 0.0001).</p><p><strong>Conclusions: </strong>A proactive model suggesting addiction consultation in patients with likely opioid use disorder resulted in an increased proportion of completed consultations as compared to usual care. Addiction consultations were associated with initiation or continuation of medication for OUD, demonstrating the value of addiction consultation services in the hospital. More research is needed to show the potential impact of addiction consultation services on health outcomes.</p>","PeriodicalId":52388,"journal":{"name":"Journal of the Academy of Consultation-Liaison Psychiatry","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144039742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Clinical Utility and Impact of Phosphatidylethanol Testing in Liver Transplantation Evaluations\" [Journal of the Academy of Consultation-Liaison Psychiatry 65(2024) 157-166].","authors":"David C Fipps, Rachel Meyer, Jeffrey Woods, Kymberly Watt, Terry Schneekloth, Jennifer Gifford, Bhanu Prakash Kolla","doi":"10.1016/j.jaclp.2025.04.004","DOIUrl":"https://doi.org/10.1016/j.jaclp.2025.04.004","url":null,"abstract":"","PeriodicalId":52388,"journal":{"name":"Journal of the Academy of Consultation-Liaison Psychiatry","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144042930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}